FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its ...
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
ophthalmologytimes4 小时
FDA accepts NDA for epi-on corneal crosslinking Epoxia from Glaukos
A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.
Le Lézard6 小时
Glaukos Announces FDA Acceptance of NDA Submission for Epioxatm
Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it ...
Scientific Research Publishing14 小时
Huge Pelvic GIST Got Good Control after Resistance to Tyrosine Kinase Inhibitors by SIB ...
Chen, D. and Li, L. (2025) Huge Pelvic GIST Got Good Control after Resistance to Tyrosine Kinase Inhibitors by SIB-IMRT: A ...